ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally.
+ 2 more risks
Adequate balance sheet with limited growth.
Share Price & News
How has ImpediMed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IPD's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned -18.8% over the past year.
Price Volatility Vs. Market
How volatile is ImpediMed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Much Are ImpediMed Limited (ASX:IPD) Insiders Spending On Buying Shares?
1 month ago | Simply Wall StThe ImpediMed (ASX:IPD) Share Price Is Down 88% So Some Shareholders Are Rather Upset
1 month ago | Simply Wall StWhat Kind Of Shareholder Appears On The ImpediMed Limited's (ASX:IPD) Shareholder Register?
Is ImpediMed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IPD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IPD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IPD is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: IPD is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IPD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IPD is good value based on its PB Ratio (1.1x) compared to the AU Medical Equipment industry average (3.4x).
How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IPD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IPD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IPD's revenue (46.8% per year) is forecast to grow faster than the Australian market (4% per year).
High Growth Revenue: IPD's revenue (46.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPD is forecast to be unprofitable in 3 years.
How has ImpediMed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPD is currently unprofitable.
Growing Profit Margin: IPD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPD is unprofitable, and losses have increased over the past 5 years at a rate of -9.9% per year.
Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: IPD has a negative Return on Equity (-138%), as it is currently unprofitable.
How is ImpediMed's financial position?
Financial Position Analysis
Short Term Liabilities: IPD's short term assets (A$17.1M) exceed its short term liabilities (A$6.1M).
Long Term Liabilities: IPD's short term assets (A$17.1M) exceed its long term liabilities (A$588.0K).
Debt to Equity History and Analysis
Debt Level: IPD is debt free.
Reducing Debt: IPD has not had any debt for past 5 years.
Inventory Level: IPD has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if IPD's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IPD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.9% each year
What is ImpediMed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IPD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon is a seasone ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD1.54M) is above average for companies of similar size in the Australian market ($USD245.57K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
|MD, CEO||7.67yrs||AU$2.50m||0.31% A$64.1k|
|Senior Vice President of Operations & Strategic Planning||1.17yrs||AU$751.78k||0.031% A$6.4k|
|Chief Technology Officer||1.67yrs||AU$1.13m||no data|
|Senior Vice President of R&D and Technology||no data||AU$884.15k||0.18% A$36.6k|
|Senior Vice President of Medical Affairs||no data||AU$795.44k||0.23% A$47.4k|
|Executive VP of Finance & Interim CFO||no data||no data||no data|
|Vice President of Human Resources||1.17yrs||no data||no data|
|Chief Medical Officer||5.42yrs||no data||no data|
|Company Secretary||5.17yrs||no data||no data|
|Medical Director||10yrs||no data||no data|
Experienced Management: IPD's management team is seasoned and experienced (5.2 years average tenure).
|MD, CEO||7.67yrs||AU$2.50m||0.31% A$64.1k|
|Non-Executive Chairman||2.25yrs||AU$160.18k||0.15% A$30.4k|
|Non-Executive Director||2.25yrs||AU$73.91k||0.041% A$8.3k|
|Non-Executive Director||3yrs||AU$114.94k||0.097% A$19.8k|
|Non-Executive Director||2.83yrs||AU$82.13k||0.067% A$13.6k|
|Non-Executive Director||3yrs||AU$94.04k||0.076% A$15.5k|
Experienced Board: IPD's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.
ImpediMed Limited's company bio, employee growth, exchange listings and data sources
- Name: ImpediMed Limited
- Ticker: IPD
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$20.442m
- Shares outstanding: 511.05m
- Website: https://www.impedimed.com
Number of Employees
- ImpediMed Limited
- 50 Parker Court
- Unit 1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IPD||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
|IPDQ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 2007|
|IPD||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
|39I||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 2007|
ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 10:40|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.